AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology.
The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.
It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions.
The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010.
BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Country | IL |
IPO Date | Jul 27, 2011 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 79 |
CEO | Philip A. Serlin CPA, M.B.A., CPA, MBA |
Contact Details
Address: Modi’in Technology Park Hevel Modi'in, IL | |
Website | https://www.biolinerx.com |
Stock Details
Ticker Symbol | BLRX |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001498403 |
CUSIP Number | 09071M205 |
ISIN Number | US09071M2052 |
Employer ID | 00-0000000 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Philip A. Serlin CPA, M.B.A., CPA, MBA | Chief Executive Officer |
Mali Zeevi CPA, CPA | Chief Financial Officer |
Dr. Ella Sorani Ph.D. | Chief Development Officer |
Holly W. May M.B.A. | President of BioLineRx USA |
John Lacey | Head of Corporate Communications & Investor Relations |
Raziel Fried | Treasurer & Budgetary Control Director |
Tsipi Keren-Lehrer B.Sc., L.L.B. | Head of BD & Strategic Advisor |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jan 10, 2025 | SCHEDULE 13G | Filing |
Jan 07, 2025 | 6-K | Filing |
Jan 07, 2025 | 424B5 | Filing |
Jan 06, 2025 | 6-K | Filing |
Dec 27, 2024 | S-8 | Filing |
Nov 25, 2024 | 6-K | Filing |
Nov 21, 2024 | 6-K | Filing |
Nov 21, 2024 | 424B5 | Filing |
Nov 12, 2024 | 6-K | Filing |
Nov 05, 2024 | 6-K | Filing |